Captrust Financial Advisors boosted its holdings in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 43.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,330 shares of the life sciences company’s stock after buying an additional 707 shares during the period. Captrust Financial Advisors’ holdings in Integra Lifesciences were worth $105,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund boosted its holdings in Integra Lifesciences by 4,410.0% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,254,051 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 1,226,245 shares during the period. Enlightenment Research LLC bought a new position in Integra Lifesciences in the 4th quarter valued at $32,000. Legacy Financial Advisors Inc. bought a new position in Integra Lifesciences in the 4th quarter valued at $33,000. Fort L.P. bought a new position in Integra Lifesciences in the 4th quarter valued at $34,000. Finally, NumerixS Investment Technologies Inc boosted its holdings in Integra Lifesciences by 100.1% in the 4th quarter. NumerixS Investment Technologies Inc now owns 2,801 shares of the life sciences company’s stock valued at $124,000 after purchasing an additional 1,401 shares during the period. Institutional investors and hedge funds own 83.11% of the company’s stock.

In other news, major shareholder Richard E. Caruso sold 30,128 shares of Integra Lifesciences stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $56.06, for a total transaction of $1,688,975.68. Following the completion of the sale, the insider now directly owns 143,384 shares of the company’s stock, valued at approximately $8,038,107.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.

NASDAQ IART opened at $56.01 on Monday. Integra Lifesciences Holdings Corp has a 52-week low of $42.14 and a 52-week high of $67.50. The company has a quick ratio of 1.88, a current ratio of 2.95 and a debt-to-equity ratio of 0.97. The firm has a market cap of $4.78 billion, a PE ratio of 23.14, a P/E/G ratio of 1.63 and a beta of 0.96.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, February 21st. The life sciences company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.03. Integra Lifesciences had a net margin of 4.13% and a return on equity of 16.02%. The company had revenue of $383.30 million during the quarter, compared to the consensus estimate of $382.33 million. During the same period in the previous year, the firm posted $0.64 EPS. The firm’s revenue was up 4.0% compared to the same quarter last year. On average, equities analysts expect that Integra Lifesciences Holdings Corp will post 2.68 EPS for the current year.

IART has been the subject of several analyst reports. Zacks Investment Research raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Monday, February 4th. BidaskClub raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. Credit Suisse Group initiated coverage on shares of Integra Lifesciences in a report on Monday, December 17th. They issued an “outperform” rating and a $57.00 price target for the company. Finally, SunTrust Banks initiated coverage on shares of Integra Lifesciences in a report on Thursday, January 3rd. They issued a “buy” rating and a $56.00 price target for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company’s stock. Integra Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $60.67.

TRADEMARK VIOLATION NOTICE: “Captrust Financial Advisors Acquires 707 Shares of Integra Lifesciences Holdings Corp (IART)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2019/03/18/captrust-financial-advisors-acquires-707-shares-of-integra-lifesciences-holdings-corp-iart.html.

Integra Lifesciences Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: Return on Equity (ROE)

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.